These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 11766266)
1. [Level of autoantibodies to opiate receptors in blood of patients with opiate addiction]. Bychkov ER; Vostrikov VV; Kruputskiĭ EM; Karandashova GF; Grinenko AIa; Dambinova SA Vopr Med Khim; 2001; 47(5):547-53. PubMed ID: 11766266 [TBL] [Abstract][Full Text] [Related]
2. [Determination of antibodies to opiate receptors by latex agglutination and immunoenzyme analysis]. Kharitonova AV; Bychkov ER; Granstrem OK; Poliakov IuI; Men'shikova AIu; Evseeva TG; Dambinova SA Biomed Khim; 2003; 49(1):80-5. PubMed ID: 14569876 [TBL] [Abstract][Full Text] [Related]
3. Specific changes in levels of autoantibodies to glutamate and opiate receptors induced by morphine administration in rats. Granstrem O; Adriani W; Shumilina M; Izykenova G; Dambinova S; Laviola G Neurosci Lett; 2006 Jul; 403(1-2):1-5. PubMed ID: 16687214 [TBL] [Abstract][Full Text] [Related]
4. Autoantibodies against opioid or glutamate receptors are associated with changes in morphine reward and physical dependence in mice. Capone F; Adriani W; Shumilina M; Izykenova G; Granstrem O; Dambinova S; Laviola G Psychopharmacology (Berl); 2008 May; 197(4):535-48. PubMed ID: 18265961 [TBL] [Abstract][Full Text] [Related]
5. Drug dependence and abuse potential of tramadol. Liu ZM; Zhou WH; Lian Z; Mu Y; Ren ZH; Cao JQ; Cai ZJ Zhongguo Yao Li Xue Bao; 1999 Jan; 20(1):52-4. PubMed ID: 10437125 [TBL] [Abstract][Full Text] [Related]
6. Recombinant mu-delta receptor as a marker of opiate abuse. Dambinova SA; Izykenova GA Ann N Y Acad Sci; 2002 Jun; 965():497-514. PubMed ID: 12105125 [TBL] [Abstract][Full Text] [Related]
7. Differential regulation of RGS proteins in the prefrontal cortex of short- and long-term human opiate abusers. Rivero G; Gabilondo AM; García-Fuster MJ; La Harpe R; García-Sevilla JA; Meana JJ Neuropharmacology; 2012 Feb; 62(2):1044-51. PubMed ID: 22056472 [TBL] [Abstract][Full Text] [Related]
8. Influence of the dose on the severity of opiate withdrawal symptoms during methadone detoxification. Glasper A; Gossop M; de Wet C; Reed L; Bearn J Pharmacology; 2008; 81(2):92-6. PubMed ID: 17952010 [TBL] [Abstract][Full Text] [Related]
9. [Is premature termination of opiate detoxification due to intensive withdrawal or craving?]. Scherbaum N; Heppekausen K; Rist F Fortschr Neurol Psychiatr; 2004 Jan; 72(1):14-20. PubMed ID: 14745685 [TBL] [Abstract][Full Text] [Related]
10. Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users. Lubman D; Koutsogiannis Z; Kronborg I Drug Alcohol Rev; 2003 Dec; 22(4):433-6. PubMed ID: 14660133 [TBL] [Abstract][Full Text] [Related]
11. Benzodiazepine co-dependence exacerbates the opiate withdrawal syndrome. de Wet C; Reed L; Glasper A; Moran P; Bearn J; Gossop M Drug Alcohol Depend; 2004 Oct; 76(1):31-5. PubMed ID: 15380286 [TBL] [Abstract][Full Text] [Related]
12. Rapid detoxification from opioid dependence under general anaesthesia versus standard methadone tapering: abstinence rates and withdrawal distress experiences. Krabbe PF; Koning JP; Heinen N; Laheij RJ; van Cauter RM; De Jong CA Addict Biol; 2003 Sep; 8(3):351-8. PubMed ID: 13129838 [TBL] [Abstract][Full Text] [Related]
13. Changes in mu opioid receptors and rheological properties of erythrocytes among opioid abusers. Zeiger AR; Patkar AA; Fitzgerald R; Lundy A; Ballas SK; Weinstein SP Addict Biol; 2002 Apr; 7(2):207-17. PubMed ID: 12006216 [TBL] [Abstract][Full Text] [Related]
14. [Symptoms of hallucinogen and opiate use and withdrawal syndrome]. Ladewig D Wien Med Wochenschr; 1981 Mar; 131(5):115-8. PubMed ID: 7233905 [No Abstract] [Full Text] [Related]
15. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients? Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244 [TBL] [Abstract][Full Text] [Related]
16. [Addiction characteristics as prognostic factors in opiate dependence treated with naltrexone]. Madoz-Gúrpide A; Barbudo del Cura E; Leira Sanmartín M; Navio Acosta M; Villoria Borrego L; Ochoa Mangado E Actas Esp Psiquiatr; 2004; 32(4):199-210. PubMed ID: 15232748 [TBL] [Abstract][Full Text] [Related]
17. Opiate addiction in China: current situation and treatments. Tang YL; Zhao D; Zhao C; Cubells JF Addiction; 2006 May; 101(5):657-65. PubMed ID: 16669899 [TBL] [Abstract][Full Text] [Related]
18. Factors affecting the outcome of methadone maintenance treatment in opiate dependence. Kamal F; Flavin S; Campbell F; Behan C; Fagan J; Smyth R Ir Med J; 2007 Mar; 100(3):393-7. PubMed ID: 17491538 [TBL] [Abstract][Full Text] [Related]
19. Decreased nociceptive sensitivity: a biological risk marker for opiate dependence? Lehofer M; Liebmann PM; Moser M; Legl T; Pernhaupt G; Schauenstein K; Zapotoczky HG Addiction; 1997 Feb; 92(2):163-6. PubMed ID: 9158227 [TBL] [Abstract][Full Text] [Related]
20. [Cognitive dysfunctions in patients with alcohol dependence]. Nowakowska K; Jabłkowska K; Borkowska A Psychiatr Pol; 2007; 41(5):693-702. PubMed ID: 18421924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]